Skip to main content
. 2016 Jul 1;10(8):1296–1304. doi: 10.1016/j.molonc.2016.06.004

Figure 3.

Figure 3

The survival of the profile‐defined responder and non‐responder groups when calculated for all glioblastoma patients in the TCGA. In order to determine whether the profile‐based definitions of responder and non‐responder groups are specific to patients treated with BEV, the response score was calculated and a cut‐off score of 0 was used to test all the patients in the TCGA, regardless of their treatment (not including those patients treated with BEV). The profile‐defined responder groups were not associated with prognosis (HR BEV‐treated training set = 0.16, HR bev‐treated test set 0.34, HR all treatments = 0.84). This suggests that the profile predicts prognosis more strongly in BEV treated glioblastoma.